Powered by

Sullivan & Cromwell replaces Kirkland as Teva's adviser for proposed $43bn acquisition of Mylan

Jun 22, 2015 - The Lawyer
Mergers and Acquisitions

Sullivan & Cromwell, along with a host of US, Dutch and Israeli firms, is representing Teva Pharmaceuticals as it seeks to acquire rival Mylan for $43bn, having replaced Kirkland & Ellis as the company's adviser. 

Sullivan & Cromwell is acting for Teva with a corporate team consisting of New York partners Joseph Frumkin and Krishna Veeraraghavan, London partners Tim Emmerson and Ben Perry and Los Angles partner Eric Krautheimer. Partners Matthew Friestedt and Davis Wang are also advising ...